Location of an epitope shared by Alzheimer's amyloid peptide and brain creatine kinase using a newly developed monoclonal antibody  by Cazorla, Pilar et al.
ELSEVIER Biochimica et Biophysica Acta 1270 (1995) 149-156 
BB 
Biochi~ic~a et Biophysica A~ta 
Location of an epitope shared by Alzheimer's amyloid peptide and brain 
creatine kinase using a newly developed monoclonal antibody 
Pilar Cazorla, Jesfis Aldudo, Cristina Haas, Jesfis Vfizquez, Fernando Valdivieso, 
Maria J. Bullido * 
Centro de Biologla Molecular "Severo Ochoa" (CSIC-UAM), Universidad Aut6noma de Madrid, 28049 Madrid, Spain 
Received 22 July 1994; accepted 2December 1994 
Abstract 
Amyloid plaques, composed mainly by a peptide termed A4-amyloid, derived by proteolytic processing from the amyloid precursor 
protein (APP), are a hallmark in the brain of Alzheimer's disease patients. We have prepared a collection of monoclonal antibodies as 
tools to study APP expression and proteolysis in different systems. One of these, 5AH10, raised against residues 9-22 of A4-peptide, was 
selected for its ability to recognize only A4 subpeptides having the intact APP-secretase target sequence, as well as whole recombinant 
APP. By using synthetic subpeptides, we have located 5AH10 epitope between amino acids 15 and 22 of A4. In addition, 5AH10 showed 
a strong immunoreactivity to a 47 kDa protein present in rat brain extracts, that was identified as the B (brain specific) subunit of creatine 
kinase by immunochemical data and direct N-terminal sequencing. The cross-reaction observed is most probably due to a high degree of 
sequence identity between amino acids 15 to 22 of A4 peptide and amino acids 9 to 16 of rat B creatine kinase. 5AH10 did not recognize 
the muscle specific isoform (M subunit) of rat creatine kinase, nor the B subunit of human and rabbit creatine kinase, suggesting that 
glutamine at first position of the epitope is essential for antigen recognition by 5AH10. 
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1. Introduction 
Cerebral amyloid depositions (plaques) found in the 
parenchyma and in blood vessels are prominent findings in 
Alzheimer's disease (AD). Whilst plaques are numerous in 
AD brains, they do occur in normal aged people in lower 
numbers. These plaques are protein aggregates composed 
mainly by a 39-42 amino acid peptide [1,2], termed 
A4-amyloid, which is derived from a larger precursor 
protein (APP) having the features of a typical membrane 
glycoprotein [3]. Expression of APP is complex. The RNA 
transcript undergoes differential splicing giving mRNAs 
Abbreviations: AD, Alzheimer's Disease; APP, amyloid precursor 
protein; BSA, bovine serum albumin; CK, creatine kinase; ELISA, 
enzyme-linked immunosorbent assay; Ig, immunoglobulin; mAb; mono- 
clonal antibody; PAGE, polyacrylamide gel electrophoresis; PBS, phos- 
phate-buffered (10 mM, pH 7.2) saline; PBST, PBS supplemented with 
0.05% Tween-20; SDS, sodium dodecyl sulfate; 2D-IEF/SDS-PAGE, 
two dimensional isoeleetrofocusing/SDS-polyacrylamide gel lec- 
trophoresis. 
* Corresponding author. Fax: +34 1 3974799. 
0925-4439/95/$09.50 © 1995 Elsevier Science B.V. All rights reserved 
SSDI 0925-4439(94)00083-2 
coding for different APP isoforms [4,5]. APP is also 
post-translationally modified and compartmentalized to 
different cell locations. APP is processed by multiple 
proteolytic pathways, which lead to the secretion or intra- 
cellular degradation of APP fragments [6]. 
The mechanism by which A4-amyloid protein is de- 
rived from its precursor is not clear. The major APP 
proteolytic pathway in neuronal cell lines includes a cleav- 
age inside the A4-amyloid sequence by a still unknown 
protease, that generates a large fragment released to the 
extracellular medium and a 10 kDa C-terminal fragment, 
which remains anchored to the cell membrane [7]. It was, 
therefore, initially thought hat A4-amyloid production was 
due to an 'aberrant' APP proteolysis. However, more 
recent data have shown that the biosynthesis and metabolic 
fate of APP is both cell type and isoform-specific [8,9]; A4 
peptide has been detected in conditioned medium from 
different cells in culture [10,11] and a soluble form of 
A4-amyloid has been found in cerebrospinal f uid and 
blood from normal individuals [10,12]. Thus, it seems to 
exist at least two physiological, alternative processing 
pathways for APP, one leading to the secretion of nonamy- 
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loidogenic fragments and other, which appears to involve 
endosomes/lysosomes, capable of generating potentially 
amyloidogenic peptides. The identification of the proteases 
involved in these proteolytic pathways is under study by 
several groups (for a review, see Ref. [6]). 
Antibodies generated against synthetic peptides based 
on A4-amyloid sequence and other APP regions have a 
great potential as tools to investigate APP physiological 
processing, as well as the molecular basis of A4-amyloid 
deposition in Alzheimer's disease and in normal aging. In 
order to study APP expression and processing in various 
systems, we have prepared a collection of monoclonal 
antibodies (mAbs) specific for different A4 epitopes. In 
this work, we characterize a newly developed monoclonal 
antibody, specific for amyloidogenic derivatives of APP, 
localize the epitope recognized by this antibody between 
amino acids 15 and 22 of A4-amyloid, and show that the 
epitope is common to APP-secretase target sequence in 
A4-amyloid (amino acids 15 to 17) and the B subunit of 
rat and mouse creatine kinase. A preliminary report of 
these results has been presented in abstract form [13]. 
2. Materials and methods 
2.1. Antibodies 
To prepare 5AH10 mAb, Balb/c mice were immunized 
by intraperitoneal injection with a synthetic peptide com- 
prising amino acids 9-22 of A4-amyloid, to which a 
cysteine residue was added at both ends. Mice received 
three peptide doses of 100 ~g, first (at day 0) with 
Freund's complete adjuvant (1:1 mixture), second (at day 
15) with Freund's incomplete adjuvant and third (at day 
30) with free peptide. 10 days after the third dose, the 
presence of antibodies pecific for synthetic peptide A4 
9-22 in mice sera was assessed by ELISA. Mice with 
higher Ab titer were selected and received two intraperi- 
toneal doses (100 /xg each) of free peptide 3 and 1 day, 
respectively, before sacrifice. Splenocytes from immune 
mice were fused to the myeloma X63/Ag8653 (NP3) by 
well established methods [14]. Cultures producing antibod- 
ies recognizing A4 9-22 synthetic peptide were detected 
by ELISA and cloned by limiting dilution until hybridoma 
stabilization (three or four cloning steps). The monoclonal 
antibodies were obtained from ascites fluid of Balb/c 
mice injected with the hybridomas and purified before use 
with caprylic acid, as described [15]. Immunoglobulin (Ig) 
purity was ascertained by SDS-PAGE. 
Mouse monoclonal antibody specific for the 160 kDa 
neurofilament protein (a-NFM) was obtained from 
Boehringer-Mannheim and rabbit serum specific for S-100 
protein (c~-S100) was purchased from Serva. mAb DA4.4, 
specific for human immunoglobulin /z chain, was purified 
from ascites fluid of DA4.4 hybridoma (American Type 
Culture Collection) and used as negative control. 
2.2. Synthetic A4 peptides and purified creatine kinase 
Synthetic A4 peptides comprising residues 1-15, 9-22, 
14-28, 1-28 and 1-42 were synthesized using the solid- 
phase synthesis technique described by Merrifield [16] and 
modified by Houghten [17] in the laboratory of Chemistry 
of the Instituto de Inmunologla, Hospital de San Juan, 
Bogota, Colombia. All the peptides used in this study, 
except A4 1-42, contained a cysteine residue at both the 
amino and carboxy ends, in order to obtain polymers that 
increase peptide immunogenicity. Pure rabbit muscle crea- 
tine kinase was obtained from Boehringer-Mannheim. 
2.3. Enzyme-linked immunosorbent assay (ELISA) 
Poly-(vinyl chloride) 96-well plates (Costar) were coated 
with synthetic peptides resuspended in PBS (2 /xg in 50 
/~l/well) by overnight incubation at 37 ° C. Non-specific 
binding sites were blocked with PBS containing 3% (w/v) 
BSA at 37°C for 90 min. After incubation with specific 
antibodies (50 /xl/well) in PBST-BSA at 37°C for 1 h, 
plates were washed with PBST-BSA and incubated in the 
same conditions with horseradish peroxidase-coupled rab- 
bit anti-mouse inmunoglobulins (Dako). Bound peroxidase 
was detected with orto-phenilen-diamine i  the presence of 
hydrogen peroxide. Absorbance at 490 nm was determined 
in a microplate reader (Dynatech). 
2.4. Preparation of brain and muscle xtracts 
Triton-X-100-soluble and insoluble fractions were pre- 
pared using whole brains from Wistar rat, Balb/c mice 
and New Zealand rabbit and frontal lobe from human as 
described [18]. Basically, the method involves tissue solu- 
bilization in a buffer containing 0.5% Triton X-100, yield- 
ing a detergent-soluble supernatant (cytosol plus mem- 
brane) and a detergent-insoluble pellet (cytoskeleton), 
which is resuspended in a buffer containing 1% SDS. 
Total cell extracts from rat skeletal muscle were ob- 
tained by tissue homogenization i  10 mM KCI, 10 mM 
Na4P2OT, 10 mM Tris-HCl (pH 7.6), 180 mM 2- 
mercaptoetanol, 50% glycerol and 1 mM PMSF, followed 
by solubilization in SDS-PAGE sample buffer. They were 
generously provided by E. Fernandez (Centro de Biologla 
Molecular, CSIC-UAM. Madrid, Spain). 
2.5. Production of recombinant APP 
Expression of the three major APP isoforms was ac- 
complished using pMal plasmid from New England Bio- 
labs, which yields proteins fused to maltose-binding pro- 
tein (MBP). cDNA clones pSP65, generously donated by 
Dr. Beyreuther, were used to construct he plasmids 
pMalc-695 , pMalc-751 and pMalc-770, pSP65-APP vec- 
tors were digested with the restriction enzyme BanI, re- 
cessed 3' termini filled with Klenow fragment and finally 
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subjected to a HindlII digestion, pMalc (plH821) vector 
was digested with the restriction enzymes StuI and HindlII. 
The ligation mixture of each of the three APP-cDNAs with 
the digested pMal~ vector was used to transform compe- 
tent E. coli TG1 cells. Cells containing plasmids that 
coded for fusion proteins were grown and induced with 
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Fig. 1. Specificity of mAb 5AH10. (A) Scheme representing A4 9-22 peptide location into APP molecule. Shadowed part of A4 represents A4 9-22 
synthetic peptide used to generate mAb 5AH10. APP-secretase target, lysine at position 16, is indicated by an arrow. A4 subpeptides used to analyze 
5AH10 specificity are indicated below A4 sequence; all subpeptides, except A4, contained a cysteine residue at both the amino and carboxy ends. ELISA 
immunoreactivities of 5AH10 to A4 subpeptides are shown in the insert. (B) Immunoblot analysis of A4-derived synthetic subpeptides u ing mAb 5AH10. 
Peptides (4/zg per lane) were subjected to Tris-trieine SDS-PAGE under educing conditions and immunoblots were performed as described in Section 2, 
using a primary antibody concentration f 50 p.g/ml. The upper bands seen in A4 lane correspond to A4 aggregates. Molecular weight standards (M) 
were, from top to bottom: 45, 30, 20, 14, 6 an 2 kDa. (C) Recognition of the three major APP isoforms (695, 751 and 770) by mAb 5AH10 in immunoblot 
assays. E. coli cells induced to express recombinant MBP-APP fusion proteins were subjected to SDS-PAGE under educing conditions (750/zl of culture 
per lane) and immunoblotting using 5AH10 at 50 p.g/ml. As a control, induced bacteria transformed with p-Malc (MBP) were used. Molecular weight 
standards (M) were from top to bottom: 200, 116, 97, 66 and 45 kDa. In both ELISA and immunoblot assays, an isotype-matched, irrelevant mAb was 
used as negative control (data not shown). 
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isopropyl thio-fl-D-galactosidase. Bacterial cells were sedi- 
mented by low-speed centrifugation and directly resus- 
pended in SDS-PAGE sample buffer. 
2.6. Immunoblot 
Synthetic peptides and protein extracts, after being sub- 
jected to SDS-PAGE under reducing conditions, or to two 
dimensional electrophoresis (2D-IEF/SDS-PAGE): iso- 
electrofocusing followed by SDS-PAGE under reducing 
conditions [19], were electroblotted onto 0.45 /xm nitro- 
cellulose membranes (Bio-Rad) in a buffer containing 25 
mM Tris (pH 8.6), 200 mM glycine, 10% methanol and 
0,04% SDS. Nonspecific reactivity was blocked by 
overnight incubation at 4 ° C in PBS containing 3% (w/v) 
BSA and 0.2% Tween-20. After incubation at room tem- 
perature for 2 h with the specific mAbs resuspended in
PBS containing 1% (w/w) BSA and 0.05% Tween-20 
(PBST-BSA), membranes were washed in PBST and the 
bound antibody was detected incubating with biotinylated 
sheep anti-mouse Ig (Boehringer-Mannheim) or goat anti- 
rabbit Ig (Vector) in PBST-BSA, followed by strepta- 
vidin-horseradish peroxidase (Boehringer-Mannheim) in 
the same buffer. Blots were then developed using the ECL 
system (Amersham). 
2.7. N-terminal sequencing 
Solubilized proteins from brain extracts were separated 
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Fig. 2. Immunoreactivity of 5AH10 to rat brain proteins. Soluble (S) and insoluble (I) rat brain fractions were obtained as described in Section 2. Brain 
fractions were subjected to SDS-PAGE (60/~g per lane) under educing conditions and to immunoblotting using mAb 5AH10 at 50/~g/ml .  As markers to 
monitor fraction purity, antibodies pecific for proteins representative of both soluble (anti-S100 protein, a-S100) and insoluble fractions (anti-160 kDa 
neurofilament protein, ot-NFM) were used. An isotype-matched, irrelevant mAb was used as negative control. Unspecific bands of molecular weight 68 
and 116 kDa are due to streptavidin-peroxidase binding, as they do not appear by substituting biotin labeled antiimmunoglobulins followed by 
streptavidin-peroxidase for peroxidase labeled antiimmunoglobulins (data not shown). Molecular weight standards (M) were from top to bottom: 200, 116, 
97, 66 and 45 kDa 
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onto Immobilon-P membranes (Millipore) and detected by 
Ponceau S (Sigma) staining [20]. The 47 kDa peptide was 
identified by subjecting a small portion of the membrane 
to immunoblot analysis. The 47 kDa band-containing re- 
gion of the membrane was excised, destained and placed 
into the sequencer cartridge after a brief washing with 
distilled water. Automated sequencing was done on a 
Model 473A pulsed-liquid-phase protein sequencer (Ap- 
plied Biosystems, Foster City, CA). Sequence homology 
searching was carried out using FASTA and TFASTA 
computer programs from the GCG package (Genetic Com- 
puter Group). Multiple sequence comparison analysis were 
performed using the PILEUP program from the same 
package. The databases used were PIR international 
database (NBRF-PIR) and Swiss-Prot. 
having highest stability and antibody titer. 5AH10 hy- 
bridoma was injected into the peritoneal cavity of Balb/C 
mice and the antibody produced was purified from ascites 
fluid. 
In order to localize 5AH10 epitope, recognition of 
subpeptides covering the whole A4 peptide was analyzed 
by ELISA (Fig. 1A) and immunoblot assays (Fig. 1B). The 
results permitted us to localize 5AH10 epitope between 
amino acids 14 and 22 of A4 peptide. Since in both assays, 
mAb 5AH10 recognized only the peptides having APP- 
secretase target sequence, this antibody was considered of 
high interest for its potential ability to distinguish between 
amyloidogenic and non-amyloidogenic APP fragments. By 
the other hand, as shown in Fig. 1C, 5AH10 was also able 
to recognize the three major isoforms of APP obtained as 
recombinant fusion proteins in E. coli. 
3. Results 
3.1. Monoclonal antibody generation and epitope location 
into A4-amyloid 
In an attempt to obtain monoclonal antibodies capable 
of distinguishing amyloidogenic from non-amyloidogenic 
peptides derived from APP, we immunized mice with a 
synthetic peptide spanning the APP-secretase target region 
(amino acids 9-22 of A4-amyloid) (Fig. 1A). From the 
hybridomas obtained, 5AH10 was selected as the one 
3.2. Identification of a 47 kDa antigen recognized by 
5AHI O in soluble brain extracts. 
We subsequently proceed to the study of polypeptides 
recognized by 5AH10 in brain. Rat brains were homoge- 
nized in a buffer containing Triton X-100 in order to 
separate cytosolic plus membrane (soluble) and cyto- 
skeletal (insoluble) fractions. When these fractions were 
subjected to immunoblot assays, mAb 5AH10 recognized a 
major band having a molecular weight of 47 kDa, which 
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Fig. 3. Immunoblot analysis of soluble rat brain extract after 2D-IEF/SDS-PAGE. 50 /~g of soluble rat brain fraction proteins were subjected to 
2D-IEF/SDS-PAGE and either silver stained (left panel), or electroblotted and analyzed by immunoblot using mAb 5AH10 (right panel) at 50 /~g/ml  as 
described in Section 2. The position of B47 is indicated by an arrow. Molecular weight standards (M) were from top to bottom: 200, 116, 97, 66 and 45 
kDa. pH values are indicated by numbers at the bottom 
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soluble fraction (Fig. 2). The very weak recognition of 
whole APP molecules can be attributed to the fact that this 
monoclonal antibody was generated against a synthetic 
peptide, and may not react to native protein, as has been 
shown for other anti-peptide antibodies [21]. 
As a further step of analysis, soluble rat brain extracts 
were subjected to 2D- IEF /SDS-PAGE,  followed by im- 
munoblot analysis using mAb 5AH10. As shown in Fig. 3, 
5AH10 stained essentially one polypeptide showing a 
molecular weight of 47 kDa and an isoelectric point of 
around 5.5. 
In order to unambiguously identify the B47 protein, this 
band was electroblotted onto Immobilon P membranes and 
subjected to direct N-terminal sequencing. The sequence 
obtained was then employed for extensive protein database 
searching. As shown in Fig. 4A, the sequence matched 
exactly the N-terminus of the brain isoform (B subunit) of 
rat creatine kinase (rat B-CK). Furthermore, the apparent 
molecular weight and isoelectric point of B47 were also in 
good agreement with the data reported for rat B-CK [22]. 
These results clearly demonstrated that mAb 5AH10 was 
not detecting an APP-derived polypeptide in soluble brain 
extracts, but cross-reacted with a non-related protein. 
3.3. 5AHIO Epitope in creatine kinases 
An analysis of sequence similarities between the im- 
munogen used to obtain 5AH10 (A4 9-22)  and rat B-CK 
A 
B47:  
Rat  B -CK:  
H 2 N-  PFSNXHNTQKLXFPX 
llll illlll II 
H 2 N-  PFSNSHNTQKLRFPAEDE-  • • • 
B 
A4(9-22) :  
Rat  B -CK:  
Mouse  B -CK:  
Human B-CK:  
Rabb i t  B -CK:  
Rat  M-CK:  
Rabb i t  M-CK:  
P~EFP- . .  
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Fig. 4. 5AH10 reactivity to creatine kinases. (A) Identification of B47 by N-terminal sequencing. Soluble rat brain extract (100 #g) was subjected to 
SDS-PAGE and electroblotted onto PVDF membranes. The B47-containing region was excised and subjected todirect N-terminal sequencing asdescribed 
in Section 2. Amino acids in cycles 5 and 12 could not be identified ue to the low quantities employed for the analysis. (B) Analysis of sequence 
homology between A4 9-22 and creatine kinases from different species and tissues. Conserved amino acids are enclosed by shadowed boxes. (C) 5AH10 
recognition of creatine kinases from different sources. Soluble extracts (60 /zg of protein per lane) from rat, mouse, human and rabbit brain, total rat 
muscle xtracts (60/zg per lane), or purified rabbit muscle creatine kinase (20 pg per lane) were subjected to immunoblot analysis using mAb 5AH10 at 
50/zg/ml as described in Section 2. An isotype-matcbed, irrelevant mAb was used as negative control (data not shown). Molecular weight standards (M) 
were from top to bottom: 66 and 45 kDa 
P. Cazorla et al. / Biochimica et Biophysica Acta 1270 (1995) 149-156 155 
showed the existence of a high degree of identity (6 out of 
8) between amino acids 15-22 of A4-amyloid and amino 
acids 9-16 of rat B-CK (Fig. 4B). Since this is the region 
of A4-amyloid peptide where 5AH10 epitope was local- 
ized (see above), the high degree of similarity encountered 
strongly suggests that the cross-reactivity of 5AH10 to rat 
B-CK is due to the amino acid sequence homology be- 
tween A4 and rat B-CK. 
In order to assess which residues were more relevant in 
antigen recognition by 5AH10, we studied the immuno- 
reactivity of this antibody to several isoforms of creatine 
kinase differing in various residues at 5AH10 epitope (Fig. 
4B). This was performed by subjecting brain and muscle 
extracts from different species, as well as a purified form 
of creatine kinase from rabbit muscle to immunoblot anal- 
ysis using 5AH10. As shown in Fig. 4C, the antibody 
clearly recognized a band in mouse brain extracts in the 
same position than in rat brain extracts. This is consistent 
with the fact that mouse B-CK is identical to rat B-CK in 
residues 9-16, where 5AH10 epitope appears to be lo- 
cated. On the contrary, human and rabbit B-CK, which 
only differ from rat B-CK in this region for a Gin to Leu 
substitution atposition 9 were not recognized by 5AH10 in 
the extracts. In addition, 5AH10 showed no reactivity to 
rat or rabbit muscle creatine kinases (M-CK), which only 
have two residues in common with peptide 9-22 from A4. 
This set of data clearly show that the epitope recognized 
by 5AH10 is located between amino acids 9-16 of rat 
B-CK and amino acids 15-22 of A4-amyloid, and that 
Glu-15 in A4-amyloid sequence is essential for antigen 
recognition, whereas Val-18 and Phe-20 can change with- 
out abrogating 5AH10 immunoreactivity. 
4. Discussion 
immunological results obtained using this antibody, as well 
as other antibodies pecific for this antigenic site, should 
be cautiously analyzed when working with animal models 
like rat or mouse. 
Reports imilar to this one have been made by different 
groups that describe cross-reactions of antibodies raised 
against A4 peptides with fibrinogen [23] or neuronal spe- 
cific enolase [24]. Since many of the studies on the pres- 
ence and distribution of A4-amyloid and APP amyloido- 
genic fragments in the brain are based on immunochemical 
approaches using monoclonal or polyclonal antibodies 
raised against A4 subpeptides, it is important o realize 
that, in some cases, these data may have been obscured by 
such cross reactions. Therefore, immunological data ob- 
tained using antibodies engineered for the detection of 
APP or APP fragments hould be confirmed by using 
alternative approaches uch as direct protein microse- 
quencing. 
Creatine kinase is a key enzyme of the energy 
metabolism (for a review, see [25]). In fact, alterations in 
cerebrospinal f uid levels of creatine kinase have been 
described following brain damage [26,27]. Since autoanti- 
bodies are well known as classical agents causing diseases 
and, indeed, human autoantibodies specific for A4-amyloid 
have been recently described [28], our results raise the 
intriguing possibility that cross-reactive pitopes might 
play some specific role in the etiology of Alzheimer's 
disease. Further investigations would be required intending 
to establish a possible relation between creatine kinase 
alterations and Alzheimer's disease. Due to its high im- 
munoreactivity o rat creatine kinase, and its ability to 
distinguish between brain (B subunit) and muscle (M 
subunit) specific isoforms, mAb 5AH10 may become a 
valuable tool for the study of this protein. 
The cross-reactivity observed between an anti-APP anti- 
body and a brain protein alerts once more against the 
routinely identification of APP fragments on the sole basis 
of immunological techniques. The sequence of peptide 
A4-amyloid 9-22 spans the APP-secretase cleavage site 
(Fig. 1), so that antibodies specific for this peptide should 
only detect he fragments which were not cleaved by the 
secretase, and are thus potentially amyloidogenic. One of 
the monoclonal antibodies generated using A4 9-22 sub- 
peptide as immunogen, mAb 5AH10, was selected as a 
potentially valuable tool since it needed APP-secretase 
target sequence integrity and could be used to specifically 
detect APP-derived amyloidogenic fragments. However, as 
demonstrated in this work, the epitope recognized by 
5AH10 showed a high degree of homology with the 
APP-unrelated brain protein creatine kinase, and this ho- 
mology was sufficient to produce a marked cross-reactivity 
of 5AH10 with this protein in crude brain extracts. Be- 
cause of its specificity, mAb 5AH10 should not produce 
'artifacts' due to cross-reactivity in human brains, but 
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